MedTrace Logo

Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B

NCT01311947 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 103

Last updated 2013-07-30

No results posted yet for this study

Summary

In order to clarify the association between HBV mutations appearing before and during interferon therapy and the therapeutic effects, serial serum samples from 100 HBeAg-positive CHB patients undergoing peginterferon alfa-2a therapy will be collected and analyzed for the mutations of preS/S gene and BCP-preC/C region, particularly for the deletion mutations. Furthermore, Real-Time PCR will be performed to measure the ratios of wild-type HBV and deletion mutant HBV before and at the end of peginterferon alfa-2a therapy. Finally, statistical analysis will be done to elucidate whether the mutations of preS/S gene and BCP-preC/C region have any relation with the therapeutic effect of peginterferon alfa-2a.

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

Peginterferon alfa-2a

Peginterferon alfa-2a at 180 ug weekly for 24 weeks

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Cheng-Yuan Peng, MD, PhD · China Medical University Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01311947 on ClinicalTrials.gov